Bli medlem
Bli medlem

Du är här


Peptonic Medical: Peptonic Medical publishes an Information Memorandum

Stockholm, November 25, 2015. Peptonic Medical AB (publ) ("Peptonic
Medical" or the "Company") - a company developing pharmaceuticals
based on oxytocin - today announces that the Information Memorandum
regarding the Company's rights issue (the "Offer") is now available
on the Company's website

· The Board of Peptonic Medical today publishes an Information
Memorandum with regards to the Offer of approximately MSEK 22.7

· Detailed information regarding the Offer is available on, and

· The subscription period is between November 27, 2015, and December
11, 2015

· Trading in subscription rights will take place between November
27, 2015, and December 9, 2015

For further information, please contact:

Johan Inborr, CEO
Phone: +46 708 853 893

About Peptonic Medical AB (publ)

Peptonic Medical AB (publ) is an innovative Swedish pharmaceutical
company developing oxytocin based products e.g. for the treatment of
menopausal symptoms, such as vaginal atrophy. Oxytocin has a long
history of safe medical use and offers an alternative to estrogen and
estrogen-like acting compounds for menopausal and postmenopausal
women. Peptonic Medical AB (publ)'s mission is to develop safe and
effective drugs based on oxytocin.


Författare ATORG

Tala om vad ni tycker

Tala om vad ni tycker

Ni är just nu inne på en betaversion av nya aktiespararna. Lämna gärna feedback på vad ni tycker i formuläret nedan.